Objective: To evaluate the correlation of cerebrospinal uid total protein and serum neutrophil-to-lymphocyte ratio with the clinical outcomes and the various clinical and electrophysiological variants of Guillain-Barre syndrome. Study Design: Cross-sectional study. Place and Duration of the Study: Department of Neurology, Mayo Hospital and King Edward Medical University, Lahore, Pakistan, from November 2022 to April 2023. Methodology: Fourty-six Guillain-Barre syndrome patients, aged 12-70 years, were included in the study diagnosed by using the Brighton's criteria. Functional disability and respiratory insu ciency were assessed by using the modi ed Hughes disability score and the Erasmus Guillain-Barre syndrome respiratory insu ciency score, respectively. Serum neutrophil-to-lymphocyte ratio and cerebrospinal uid total protein were calculated for each patient at the time of admission. Results: Axonal variants had a higher mean neutrophil-to-lymphocyte ratio (5.29 ± 4.38) than demyelinating variants (4.71 ± 3.4) and Miller-Fischer syndrome (3 ± 2.828). This ratio was positively correlated with the modi ed Hughes s disability score (r = 0.790, p = 0.001) and the Erasmus Guillain-Barre syndrome respiratory insu ciency score (r = 0.936, p = 0.002). Mean cerebrospinal uid total protein was higher for demyelinating (218 ± 136 mg/dl) than axonal variants (86 ± 56 mg/dl) and Miller-Fischer syndrome (34 ± 21 mg/dl). However, higher modi ed Hughes disability score (4-6) (r = 0.020, p = 0.117) and a high Erasmus Guillain-Barre syndrome respiratory insu ciency score (5-7) (r = 0.115, p = 0.302) did not signi cantly a ect mean cerebrospinal uid total proteins. Conclusion: Serum neutrophil-to-lymphocyte ratio can be regarded as a reliable biomarker to assess disease severity and clinical outcome in Guillain-Barre syndrome. Cerebrospinal uid total protein is a poor predictor of the prognosis and severity of Guillain-Barre syndrome.